| DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma MY Teo, RM Bambury, EC Zabor, E Jordan, H Al-Ahmadie, ME Boyd, ... Clinical cancer research 23 (14), 3610-3618, 2017 | 244 | 2017 |
| Golgi biogenesis in Toxoplasma gondii L Pelletier, CA Stern, M Pypaert, D Sheff, HM Ngô, N Roper, CY He, K Hu, ... Nature 418 (6897), 548-552, 2002 | 226 | 2002 |
| Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase II study A Thomas, R Vilimas, C Trindade, R Erwin-Cohen, N Roper, L Xi, ... Journal of Thoracic Oncology 14 (8), 1447-1457, 2019 | 164 | 2019 |
| Adult cancer clinical trials that fail to complete: an epidemic? KD Stensland, RB McBride, A Latif, J Wisnivesky, R Hendricks, N Roper, ... Journal of the National Cancer Institute 106 (9), dju229, 2014 | 137 | 2014 |
| Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer N Roper, AL Brown, JS Wei, S Pack, C Trindade, C Kim, O Restifo, S Gao, ... Cell reports medicine 1 (1), 2020 | 104 | 2020 |
| APOBEC mutagenesis and copy-number alterations are drivers of proteogenomic tumor evolution and heterogeneity in metastatic thoracic tumors N Roper, S Gao, TK Maity, AR Banday, X Zhang, A Venugopalan, ... Cell reports 26 (10), 2651-2666. e6, 2019 | 101 | 2019 |
| SCLC-CellMiner: a resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures C Tlemsani, L Pongor, F Elloumi, L Girard, KE Huffman, N Roper, ... Cell reports 33 (3), 2020 | 93 | 2020 |
| Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer N Roper, MJ Velez, A Chiappori, YS Kim, JS Wei, S Sindiri, N Takahashi, ... Nature Communications 12 (1), 3880, 2021 | 86 | 2021 |
| Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing N Roper, B Storer, R Bona, M Fang The Journal of Molecular Diagnostics 12 (3), 283-291, 2010 | 82 | 2010 |
| Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM-and PUMA-mediated apoptosis K Tanaka, AY Helena, S Yang, S Han, SD Selcuklu, K Kim, S Ramani, ... Cancer Cell 39 (9), 1245-1261. e6, 2021 | 66 | 2021 |
| The landscape of precision cancer medicine clinical trials in the United States N Roper, KD Stensland, R Hendricks, MD Galsky Cancer treatment reviews 41 (5), 385-390, 2015 | 60 | 2015 |
| Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies J Mascarenhas, N Roper, P Chaurasia, R Hoffman Clinical epigenetics 2, 197-212, 2011 | 60 | 2011 |
| The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia X Leleu, W Xie, M Bagshaw, R Banwait, R Leduc, N Roper, E Weller, ... Clinical Cancer Research 17 (9), 3013-3018, 2011 | 58 | 2011 |
| Ethanol impaired neuronal migration is associated with reduced aspartyl-asparaginyl-β-hydroxylase expression JJ Carter, M Tong, E Silbermann, SA Lahousse, FF Ding, L Longato, ... Acta neuropathologica 116 (3), 303-315, 2008 | 56 | 2008 |
| New insights on the genetics of pheochromocytoma and paraganglioma and its clinical implications S Jhawar, Y Arakawa, S Kumar, D Varghese, YS Kim, N Roper, F Elloumi, ... Cancers 14 (3), 594, 2022 | 47 | 2022 |
| Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models D Lissa, N Takahashi, P Desai, I Manukyan, CW Schultz, V Rajapakse, ... Nature communications 13 (1), 2023, 2022 | 41 | 2022 |
| Impact of industry collaboration on randomised controlled trials in oncology A Linker, A Yang, N Roper, E Whitaker, D Korenstein European Journal of Cancer 72, 71-77, 2017 | 33 | 2017 |
| Parathyroid carcinoma: Incidence, survival analysis, and management: A study from the SEER database and insights into future therapeutic perspectives A Ullah, J Khan, A Waheed, N Sharma, EK Pryor, TR Stumpe, ... Cancers 14 (6), 1426, 2022 | 32 | 2022 |
| Extrachromosomal DNA amplification contributes to small cell lung cancer heterogeneity and is associated with worse outcomes LS Pongor, CW Schultz, L Rinaldi, D Wangsa, CE Redon, N Takahashi, ... Cancer discovery 13 (4), 928-949, 2023 | 22 | 2023 |
| Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V*[S] X Zhang, KD Nguyen, PA Rudnick, N Roper, E Kawaler, TK Maity, ... Molecular & Cellular Proteomics 18 (4), 622-641, 2019 | 19 | 2019 |
